We, therefore, evaluated the therapeutic inhibition of GPR84 by these two novel antagonists in comparison to selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, in three NASH mouse models. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.